Scarica l'app Stockscreener
76.00
2.70%
-2.205
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$78.20
Aprire:
$77.53
Volume 24 ore:
342.11K
Relative Volume:
0.58
Capitalizzazione di mercato:
$2.87B
Reddito:
-
Utile/perdita netta:
$-91.00M
Rapporto P/E:
-20.71
EPS:
-3.67
Flusso di cassa netto:
$-74.38M
1 W Prestazione:
+7.28%
1M Prestazione:
-4.67%
6M Prestazione:
+24.86%
1 anno Prestazione:
+33.52%
Intervallo 1D:
$75.43
$79.48
Intervallo di 1 settimana:
$69.17
$79.48
Portata 52W:
$30.82
$99.50
Disc Medicine Inc Stock (IRON) Company Profile
Nome
Disc Medicine Inc
Settore
Industria
Telefono
(617) 674-9274
Indirizzo
321 ARSENAL STREET, SUITE 101, WATERTOWN
Confronta IRON con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IRON
Disc Medicine Inc
|
76.00 | 2.95B | 0 | -91.00M | -74.38M | -3.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.00 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
751.41 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
816.53 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
363.01 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
339.15 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Disc Medicine Inc Stock (IRON) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-03 | Ripresa | Stifel | Buy |
| 2025-07-21 | Iniziato | Truist | Buy |
| 2025-07-03 | Ripresa | Morgan Stanley | Overweight |
| 2025-06-11 | Ripresa | Raymond James | Strong Buy |
| 2025-02-27 | Iniziato | TD Cowen | Buy |
| 2024-11-05 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2024-11-04 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2024-10-23 | Iniziato | Jefferies | Buy |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-08-22 | Iniziato | Wells Fargo | Overweight |
| 2024-04-01 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2023-12-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2023-06-09 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2023-06-07 | Iniziato | H.C. Wainwright | Buy |
| 2023-05-17 | Iniziato | Raymond James | Outperform |
| 2023-04-28 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-04-21 | Iniziato | Stifel | Buy |
| 2023-04-20 | Iniziato | Morgan Stanley | Overweight |
| 2023-03-23 | Iniziato | BMO Capital Markets | Outperform |
| 2023-02-28 | Iniziato | SVB Securities | Outperform |
Mostra tutto
Disc Medicine Inc Borsa (IRON) Ultime notizie
Understanding the Setup: (IRON) and Scalable Risk - Stock Traders Daily
Disc Medicine (NASDAQ:IRON) Insider Rahul Khara Sells 1,000 Shares of Stock - MarketBeat
Disc Medicine, Sanofi, Eli Lilly Shares Slip On Reports Of FDA Increasing Review Time For Drugs Granted Priority Review Vouchers - Stocktwits
Is Disc Medicine Inc. attractive at current valuationWeekly Market Outlook & High Win Rate Trade Alerts - bollywoodhelpline.com
Assessing Disc Medicine (IRON) Valuation After FDA Review Delay And Heightened Regulatory Focus - Sahm
Disc Medicine and Sanofi reportedly face delays for FDA national priority review vouchers - MSN
Short Interest in Disc Medicine, Inc. (NASDAQ:IRON) Grows By 53.8% - MarketBeat
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Disc Medicine Analyst Remains Confident In Rare Disease Drug Despite FDA ActionDisc Medicine (NASDAQ:IRON) - Benzinga
Disc Medicine (IRON) Valuation Check As Bitopertin Wins Priority FDA Review And Commercial Plans Advance - Yahoo Finance
Reported delays to FDA reviews under new fast-track program - The Pharma Letter
FDA Shows Caution, Delays Trump-Backed Fast-Track Drugs Over Risks (UPDATED) - Benzinga
FDA Shows Caution, Delays Trump-Backed Fast-Track Drugs Over Risks (UPDATED) - Benzinga
Klein Hersh Recruits CHRO for Disc Medicine - Hunt Scanlon Media
Disc Medicine (IRON) Stock Declines Amid Market Movement - GuruFocus
What Investors Should Know About a $511K Disc Medicine Insider Sale and a 26% Stock Run - AOL.com
Exclusive: US FDA delays two drug reviews in new voucher program after safety, efficacy concerns - Reuters
US FDA delays two drug reviews in new voucher program after safety, efficacy concerns - TradingView — Track All Markets
Disc Medicine stock rating reiterated by Morgan Stanley amid FDA review - Investing.com South Africa
Stifel remains bullish on Disc Medicine stock despite potential FDA delay - Investing.com Canada
Morgan Stanley Reaffirms Positive Outlook on IRON Despite FDA Re - GuruFocus
Disc Medicine (NASDAQ:IRON) Shares Gap DownShould You Sell? - MarketBeat
Experimental drug suspended❓💊 Shares od Disc Medicine lose as much as 7% 🚨 - XTB.com
Disc Medicine (IRON) Shares Decline as FDA Review Faces Brief De - GuruFocus
Disc Medicine (IRON) Faces Review Delay for Rare Disease Drug - GuruFocus
Fda pushes back review of Sanofi's diabetes drug Tzield and Disc Medicine's blood disorder drug -documents - marketscreener.com
How Disc Medicine’s New HR Chief and Bitopertin Review Could Shape IRON’s Commercial Readiness - Sahm
Disc Medicine, Inc. (NASDAQ:IRON) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Aug Gainers: Should I hold or sell Disc Medicine Inc stock in 2025July 2025 WrapUp & Stepwise Entry/Exit Trade Alerts - Bộ Nội Vụ
Is Disc Medicine (IRON) Offering An Opportunity After Recent Volatility And DCF Valuation Gap - Yahoo Finance
Disc Medicine appoints Lisa Amaya Price as chief human resources officer - Investing.com Nigeria
Disc Medicine outlines 2026 pipeline priorities after NDA submission By Investing.com - Investing.com Nigeria
Disc Medicine Appoints Lisa Amaya Price, MBA as Chief Human Resources Officer - citybiz
Disc Medicine (IRON) Appoints New Chief Human Resources Officer - GuruFocus
Disc Medicine appoints Lisa Amaya Price as chief human resources officer By Investing.com - Investing.com India
News | decaturdailydemocrat.comDisc Medicine Appoints Lisa Amaya Price, MBA as Chief Human Resources Officer - FinancialContent
Disc Medicine (IRON) Shares Strategic Goals and Pipeline Developments for 2026 - GuruFocus
Disc Medicine outlines 2026 pipeline priorities after NDA submission - Investing.com
Disc Medicine prepares for potential 2026 bitopertin FDA decision - TipRanks
Disc Medicine Highlights Recent Achievements and Key Business Objectives and Milestones for 2026 - The Manila Times
FDA weighs new blood disorder drug as small biotech sets a pivotal 2026 - Stock Titan
The Technical Signals Behind (IRON) That Institutions Follow - Stock Traders Daily
Disc Medicine Inc Appoints Lisa Amaya Price as Chief Human Resources Officer - marketscreener.com
Disc Medicine advances bitopertin in FDA pilot program - MSN
Aug Intraday: How supply chain issues affect Disc Medicine Inc. stockPrice Action & Daily Profit Focused Stock Screening - Улправда
Will Disc Medicine Inc. stock deliver strong dividend growthWeekly Trend Recap & Detailed Earnings Play Strategies - Улправда
A Look At Disc Medicine (IRON) Valuation After Bitopertin NDA Filing And Positive DISC-0974 Phase 2 Data - Sahm
How institutional buying supports Disc Medicine Inc. stockJuly 2025 Technicals & Technical Entry and Exit Tips - Улправда
How supply chain issues affect Disc Medicine Inc. stockWeekly Trading Summary & Intraday High Probability Setup Alerts - Улправда
Aug Selloffs: Why Disc Medicine Inc. stock is favored by top institutionsJuly 2025 Opening Moves & Growth Oriented Trade Recommendations - Улправда
All You Need to Know About Disc Medicine, Inc. (IRON) Rating Upgrade to Buy - MSN
Disc Medicine Inc Azioni (IRON) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Disc Medicine Inc Azioni (IRON) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Khara Rahul | Chief Legal Officer |
Jan 20 '26 |
Sale |
69.74 |
1,000 |
69,740 |
37,793 |
| Khara Rahul | Chief Legal Officer |
Jan 02 '26 |
Option Exercise |
13.50 |
6,500 |
87,750 |
44,293 |
| Khara Rahul | Chief Legal Officer |
Jan 02 '26 |
Sale |
78.69 |
6,500 |
511,472 |
37,793 |
3.31%
2.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):